Paper42453333
Exploring the Impact of Multiple Gene Mutations on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Response in Asian Nonsmall Cell Lung Cancer Patients.
Jing R and 5 others. ACS Pharmacol Transl Sci, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Exploring the Impact of Multiple Gene Mutations on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Response in Asian Nonsmall Cell Lung Cancer Patients. Papers, record 42453333. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42453333
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Exploring the Impact of Multiple Gene Mutations on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Response in Asian Nonsmall Cell Lung Cancer Patients.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References168
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 39116914 | Ancestry-, Sex-, and Age-Based Differences of Gene Alterations in NSCLC: From the Real-World Data of Cancer Genomic Profiling Tests. | J Natl Compr Canc Netw | 2024 | https://conductscience.org/library/papers/39116914 | PubMed |
| 2 | 34249687 | Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study. | Front Oncol | 2021 | https://conductscience.org/library/papers/34249687 | PubMed |
| 3 | 34532458 | Co-mutations of epidermal growth factor receptor and BRAF in Chinese non-small cell lung cancer patients. | Ann Transl Med | 2021 | https://conductscience.org/library/papers/34532458 | PubMed |
| 4 | 22761469 | Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. | Clin Cancer Res | 2012 | https://conductscience.org/library/papers/22761469 | PubMed |
| 5 | 31749831 | Genomic Profiling of Driver Gene Mutations in Chinese Patients With Non-Small Cell Lung Cancer. | Front Genet | 2019 | https://conductscience.org/library/papers/31749831 | PubMed |
| 6 | 22327623 | RET, ROS1 and ALK fusions in lung cancer. | Nat Med | 2012 | https://conductscience.org/library/papers/22327623 | PubMed |
| 7 | 28881815 | Clinicopathological characteristics of ROS1- and RET-rearranged NSCLC in caucasian patients: Data from a cohort of 713 non-squamous NSCLC lacking KRAS/EGFR/HER2/BRAF/PIK3CA/ALK alterations. | Oncotarget | 2017 | https://conductscience.org/library/papers/28881815 | PubMed |
| 8 | 28007627 | Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs). | J Thorac Oncol | 2017 | https://conductscience.org/library/papers/28007627 | PubMed |
| 9 | 29268402 | ALK and ROS1 rearrangements, coexistence and treatment in epidermal growth factor receptor-wild type lung adenocarcinoma: a multicenter study of 732 cases. | J Thorac Dis | 2017 | https://conductscience.org/library/papers/29268402 | PubMed |
| 10 | 37543207 | Clinicogenomic Features and Targetable Mutations in NSCLCs Harboring BRAF Non-V600E Mutations: A Multi-Institutional Genomic Screening Study (LC-SCRUM-Asia). | J Thorac Oncol | 2023 | https://conductscience.org/library/papers/37543207 | PubMed |
| 11 | 28024701 | A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population. | Lung Cancer | 2017 | https://conductscience.org/library/papers/28024701 | PubMed |
| 12 | 38432445 | PIK3CA mutation as an acquired resistance driver to EGFR-TKIs in non-small cell lung cancer: Clinical challenges and opportunities. | Pharmacol Res | 2024 | https://conductscience.org/library/papers/38432445 | PubMed |
| 13 | 30231382 | Sequencing Therapy for Genetically Defined Subgroups of Non-Small Cell Lung Cancer. | Am Soc Clin Oncol Educ Book | 2018 | https://conductscience.org/library/papers/30231382 | PubMed |
| 14 | 36503478 | Efficacy and safety analyses of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy in the treatment of advanced non-small-cell lung cancer with an EGFR/TP53 co-mutation. | BMC Cancer | 2022 | https://conductscience.org/library/papers/36503478 | PubMed |
| 15 | 38795459 | Clinical treatment patterns, molecular characteristics and survival outcomes of ROS1-rearranged non-small cell lung cancer: A large multicenter retrospective study. | Lung Cancer | 2024 | https://conductscience.org/library/papers/38795459 | PubMed |
| 16 | 34257561 | Mutation Spectrum of EGFR From 21,324 Chinese Patients With Non-Small Cell Lung Cancer (NSCLC) Successfully Tested by Multiple Methods in a CAP-Accredited Laboratory. | Pathol Oncol Res | 2021 | https://conductscience.org/library/papers/34257561 | PubMed |
| 17 | 22452895 | Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. | Lancet Oncol | 2012 | https://conductscience.org/library/papers/22452895 | PubMed |
| 18 | 38371194 | Adjuvant Osimertinib in Patients With Stage IB to IIIA EGFR Mutation-Positive NSCLC After Complete Tumor Resection: ADAURA China Subgroup Analysis. | JTO Clin Res Rep | 2024 | https://conductscience.org/library/papers/38371194 | PubMed |
| 19 | 37685884 | Real-World Data on Combined EGFR-TKI and Crizotinib Treatment for Acquired and De Novo MET Amplification in Patients with Metastatic EGFR-Mutated NSCLC. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37685884 | PubMed |
| 20 | 34235088 | Peripheral Lung Squamous Carcinoma With ROS1 Rearrangement Sensitive to Crizotinib: A Case Report. | Front Oncol | 2021 | https://conductscience.org/library/papers/34235088 | PubMed |
Genes6
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| BRAF | 673 | PubTator's text mining | https://conductscience.org/library/genes/673 | NCBI Gene |
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 | NCBI Gene |
| ERBB2 | 2064 | PubTator's text mining | https://conductscience.org/library/genes/2064 | NCBI Gene |
| KRAS | 3845 | PubTator's text mining | https://conductscience.org/library/genes/3845 | NCBI Gene |
| PIK3CA | 5290 | PubTator's text mining | https://conductscience.org/library/genes/5290 | NCBI Gene |
| ROS1 | 6098 | PubTator's text mining | https://conductscience.org/library/genes/6098 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42453333
GET https://conductscience.org/api/papers/v1/42453333/references?page=2